Log inSign up
user avatar
Guardant Health
@GuardantHealth
Conquering Cancer With Data
Palo Alto, CA
guardanthealth.com
Joined June 2012
699
Following
6,488
Followers
  • user avatar
    Guardant Health
    @GuardantHealth
    Apr 1, 2021
    Our Guardant Reveal #liquidbiopsy test was approved by the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) for the detection and monitoring of minimal residual disease #MRD in patients with early-stage cancer. bit.ly/3wdczfP
  • user avatar
    Guardant Health
    @GuardantHealth
    Aug 7, 2020
    Breaking news: Guardant360 CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling in patients with any solid cancer. This is a landmark decision, demonstrating the value #liquidbiopsy delivers to oncologists and patients. bit.ly/33CN2kk
  • user avatar
    Guardant Health
    @GuardantHealth
    Oct 13, 2021
    Join experts @drgandara, Natasha Leighl, and @MDuruisseaux as they share the latest #liquidbiopsy advancements for #cancer and the value of the Guardant360 tests to support treatment decisions at the Annual @isliquidbiopsy Congress. Register here: bit.ly/30i9nnF
    Guardant Health Symposium | 2021 ISLB Congress | October 22, 2021 15:00 CEST
  • user avatar
    Guardant Health
    @GuardantHealth
    Jul 29, 2024
    We’re changing the game for #ColorectalCancer screening w/ the FDA approval of Shield, our blood test for people age 45+ at average risk. With Shield, we aim to get more people tested & catch more cancers early, when they’re most treatable. Read more: bit.ly/3WnfKzi
    00:00
    12K
  • user avatar
    Guardant Health
    @GuardantHealth
    May 2, 2022
    We’re proud to announce that Shield, our highly sensitive blood test to detect early signs of #colorectalcancer, is now available in the U.S. for adults 45 and up who are not up to date with current #screening guidelines and at average risk for #CRC. bit.ly/3OV5tGe
  • user avatar
    Guardant Health
    @GuardantHealth
    Dec 15, 2022
    Today we announced positive results from the ECLIPSE study for our blood test for the detection of colorectal cancer. Read the press release: bit.ly/3YlANTb
    10K
  • user avatar
    Guardant Health
    @GuardantHealth
    Jan 18, 2021
    We're excited to announce our partnership with @VHIO to establish the first Guardant Health #liquidbiopsy testing service in Europe, for clinical research and clinical patient care, at VHIO’s facility in Barcelona. bit.ly/3bUv6pl
  • user avatar
    Guardant Health
    @GuardantHealth
    Feb 16, 2021
    We’re excited to launch Guardant Reveal, the first blood-only #liquidbiopsy test for residual disease and recurrence monitoring of early-stage #colorectalcancer patients. #MRD bit.ly/3an9LUi
  • user avatar
    Guardant Health
    @GuardantHealth
    Feb 6, 2017
    Learn how Guardant Health's liquid biopsies can help conquer cancer with data. Read this great @WiredUK piece: bit.ly/2lhaqLD
  • user avatar
    Guardant Health
    @GuardantHealth
    Jun 22, 2021
    We proudly announce two new tests for patients with advanced cancer. Our Guardant360 Response test for treatment response monitoring and our Guardant360 TissueNext test if needed for efficient "blood-first, tissue-next" complete genomic testing. Read more: bit.ly/35MCgb3
  • user avatar
    Guardant Health
    @GuardantHealth
    Jan 13, 2020
    We’re excited to announce the COBRA study with @NRGOnc to validate the clinical utility of our molecular residual disease assay as a diagnostic biomarker for selecting which patients with stage II colon cancer need adjuvant chemotherapy. investors.guardanthealth.com/news-releases/…
  • user avatar
    Guardant Health
    @GuardantHealth
    May 23, 2024
    Today the FDA’s Medical Devices Advisory Committee panel strongly recommended FDA approval of our Shield blood test for #ColorectalCancer screening in adults age 45 and older who are at average risk for the disease. Full release: investors.guardanthealth.com/press-releases…
    4.5K
  • user avatar
    Guardant Health
    @GuardantHealth
    May 21, 2021
    We're pleased to announce our Guardant360 CDx test has received FDA approval as the first and only companion diagnostic for @JanssenUS's approved targeted treatment for use in patients with advanced non-small cell #lungcancer harboring certain mutations. bit.ly/3fyMws0
  • user avatar
    Guardant Health
    @GuardantHealth
    Mar 14, 2023
    We were proud to support the United in Blue Rally in Washington, DC yesterday organized by @FightCRC. The time to act against #ColorectalCancer is now and bringing together fierce advocates from across the #CRC community to Call on Congress is a meaningful step towards progress.
    1.2K